Cytosolic pS2 levels in 154 non small cell lung carcinomas. Correlation with other clinical and biological parameters;Estudio de la concentración citosólica de pS2 en 154 carcinomas pulmonares no microcíticos. Correlación con otros parámetros clínico-biológicos

Revista Espanola de Medicina Nuclear

Volumn 21, Issue 2, 2002, Pages 109-114

  Ruibal Morell, A ^a   Nunez M I ^a   Del Rio Ma C ^b   Garcia Diez S ^a   Rodriguez J ^c   Alvarez De Linera J A ^c  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b UNIVERSIDAD ALFONSO X EL SABIO   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Cytosol; Lung carcinoma; pS2

Indexed keywords

CA 125 ANTIGEN; CATHEPSIN D; CD44S ANTIGEN; CD44V ANTIGEN; CD44V5 ANTIGEN; CD44V6 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; NEURON SPECIFIC ENOLASE; PROTEIN PS2; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN; TFF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL CYCLE S PHASE; CELL SURFACE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOSOL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PLOIDY; PROTEIN EXPRESSION; ADENOCARCINOMA; CHEMISTRY; COMPARATIVE STUDY; EVALUATION; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD44; CA-125 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CATHEPSIN D; CYTOSOL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; S PHASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0036548408     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/s0212-6982(02)72044-2     Document Type: Article

References (37)

1. Núnez AM, Berry M, Imler JL, Chambon O. The 5′flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and c-jun protein. EMBO J 1989;8:823-9.
2. Tomassetto C, Río MC, Gautier C, Wolf C, Hareuveni M, Chambon P, et al. hsp, the domain duplicated homolog of pS2 protein is coexpressed with pS2 in stomach buy not in breast carcinoma. EMBO J 1990;9:407-14.
3. Wright NA, Poulson R, Stamp GW, Hall PA, Jeffery RE, Long-croft JM, et al. Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol 1990;160:279-84.
4. Thim L. A new family of growth factor like peptides, « Trefoil» disiphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysins), FEBE Lett 1989;25:85-90.
5. Tomasetto C, Masson R, Linares JL, Wendling V, Lefebre O, Chenard MP, et al. pS2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. Gastroenterology 2000;118:78-80.
6. Fujimoto J, Yasui W, Tahara H, Tahara E, Kudo Y, Yokozaki H, et al. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett 2000;149:125-34.
7. Taupin D, Pedersen J, Familari M, Cook G, Yeomans N, Giraud AS. Augmented intestinal trefiol factor (TFF3) and loss of pS2 (TFF1) expresson precedes metaplastic differentiation of gastric epithelium. Lab Invest 2001;81:397-408.
8. Hirota Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, et al. pS2 expression as a possible diagnostic marker of colorectal carcinoma in ulcerative colitis. Oncol Rep 2000;7:233-9.
9. Saegusa M, Hashimura M, Hara A, Okayasu I. Up-regulation of pS2 expression during the development of adenocarcinomas but not squamous cell carcinomas of the uterine cervix, independently of expression of c-jun or oestrogen and progesterone receptors. J Pathol 2000;190:554-63.
10. Speiser P, Mayerhofer K, Kucera E, Roch G, Mittelbock M, Gitsch G, et al. pS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters. Anticancer Res 1997;17:679-83.
11. Luqmani Y, Temmim L, Memon A, Parkar A, Ali M, Motawy M, et al. Immunoradiometric measurement of pS2 in breast cancer -correlation with steroid receptors and plasminogen activators. Acta Oncol 1999;38:805-14.
12. Foekens JA, del Río MC, Seguin P, Van Putten WL, Fauque J, Nap M, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990;50:3832-7.
13. Schwartz LH, Koerner FC, Edgerton SM, Sawick DM, Rio MC, Bellocq JP, et al.: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 1991;51:624-8.
14. Hurliman J, Gebhard S, Gomez F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 1993;23:239-48.
15. Ciocca DR, Elledge R: Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 2000;13:1-10.
16. Harding C, Osundeko O, Tetlow L, Faragher EB, Howell A, Bundred NJ. Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity. Br J Cancer 2000;82:354-60.
17. Higashiyama M, Doi O, Kodama K, Yokouchi H, Inaji J, Nakamori S, et al. Prognostic significance of pS2 protein expression in pulmonary adenocarcinoma. Eur J Cancer 1994;30:792-7.
18. Higashiyama M, Doi O, Kodama K, Yokuchi H, Inaji H, Tateishi R. Estimation of serum levels of pS2 protein in patients with lung cancer. Anticancer Res 1986;16:2351-5.
19. Ruibal A, Arias J, del Río MC, Núñez MJ, Piqueras V, Delgado S, et al. Estudio bioquímico de la metastatización ganglionar axilar (N) en 282 carcinomas ductales infiltrantes de mama. Importancia del paso de N- a N+<4 y del tamaño tumoral. Rev Diag Biológico 1999;48:165-73.
20. Ruibal A, Arias JI, del Río MC, Lapeña G, Schneider J, Tejerina A. Histological grade in breast cancer: association with clinical and biological deatures in a series of 229 patients. Int J Biol Markers 2001;16:56-61.
21. Suárez C, Vizoso F, Rodríguez JC, García I, Raigoso P, Allende MT, et al. Prognostic significance of cytosolic pS2 protein content in gastric cancer. Int J Biol Markers 2001;16:37-44.
22. Díez M, Maestro ML, Torres A, Hernando F, Ortega MD, Garcia Asenjo JA, et al. Epidermal growth factor receptor in nonsmall cell cancer of the lung. Arch Bronconeumol 1994;30:282-6.
23. Hsieh ET, Shepherd Fa, Tsao MS. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. Lung Cancer 2000;29:151-7.
24. Dittadi R, Gion M, Pagan V, Brazzale A, del Maschio O, Bargossi A, et al. Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue. Br J Cancer 1991;64:741-4.
25. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987;55:513-6.
26. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitaitive epidermal gowth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993;68:162-5.
27. Fujino S, Enokibori T, Tezuka N, Asado Y, Inoue S, Kato H, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996;32:2070-4.
28. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrowsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:512-22.
29. Fang K, Chen MH: Transfection of anti-sense complementary DNA of human epidermal growth factor receptor attenuates the proliferation of human non small cell lung cancer cells. Int J Cancer 1999;81:471-8.
30. Lei W, Mayotte JE, Lewitt ML. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res 1999;19:221-8.
31. Díez M, Torres A, Maestro ML, Ortega MD, Gomez A, Pollam M, et al. Prediction of survival and recurrence by serum and cytosolic levels pf CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer 1996;73:1248-54.
32. Picardo AL, Diez M, Torres A, Maestro ML, Ortega D, Hernado F, et al. Analysis of the prognostic significance of cytosolic determination of CA125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma. Cancer 1996;77:1066-72.
33. Volm M, Drings P, Mattern J, Wodrich W. Prognostic value of oncoproteins for the survival of patients with non small cell lung carcinomas. Int J Oncol 1993;2:767-72.
34. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi H, Angeletti CA, et al. Epidermal growth factor receptor (EGFR) expression in non small cell lung carcinomas correlates wirh metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995;31:178-83.
35. Cox G, Jones JL, O'Byerne KJ: Matriz mase 9 and the epidermal growth factor signal pathway in operable no-small cell lung cancer. Clin Cancer Res 2000;6:2349-55.
36. López Guerrero JA, Bolufer Gilabert P, Vera Sempere FJ, Marugan de la Concha I, Barragán González E. C-erbB2 expression and its relationship with ploidy, p53 abnormalities and epidermal gowth factor receptor content in human non-small cell lung cancer. Clin Chim Acta 1999;285:105-20.
37. Giatromanolaki A, Gorgoulis V, Chetty R, Koukourakis MI, Whitehouse R, Kittas C, et al. C-erbB2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res 1996;16:987-93.